Mereo BioPharma Group plc

Management Reports • Sep 3, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4927Z

Mereo BioPharma Group plc

03 September 2018

Mereo BioPharma Group plc

("Mereo" or the "Company")

Block Listing Application

London, 3 September 2018 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces that an application has been made to the London Stock Exchange for a block listing of  7,651,151 ordinary shares of £0.003 each in the Company ("Ordinary Shares").

These Ordinary Shares will be issued from time to time in order to satisfy the requirement to allot shares under the 2015 Plan and the Mereo BioPharma Group plc Share Option Plan.

It is expected that admission will become effective on 6 September 2018. The Ordinary Shares under the block listing will rank pari passu with the Company's existing Ordinary Shares.

Enquiries:

Mereo BioPharma Group plc	+44 (0)333 023 7300
Denise Scots-Knight, Chief Executive Officer
Richard Jones, Chief Financial Officer
Cantor Fitzgerald Europe (Nominated Adviser and Broker)	+44 (0)20 7894 7000
Phil Davies
Will Goode
Rick Thompson
RBC Capital Markets (Joint Broker)	+44 (0)20 7653 4000
Rupert Walford Jamil Miah
FTI Consulting (Public Relations Adviser)	+44 (0)20 3727 1000
Simon Conway
Brett Pollard
Burns McClellan (US Public Relations Advisor to Mereo Biopharma)	+01 (0) 212 213 0006
Lisa Burns
Steven Klass

About Mereo

Mereo is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare diseases. The portfolio currently consists of four clinical-stage product candidates, each of which were acquired from large pharmaceutical companies: BPS-804 (setrusumab) for the treatment of osteogenesis imperfecta ("OI"); MPH-966 (alvelestat) for the treatment of severe alpha-1 antitrypsin deficiency ("AATD"); BCT-197 for the treatment of acute exacerbations of chronic obstructive pulmonary disease, ("AECOPD"); and BGS-649 for the treatment of hypogonadotropic hypogonadism ("HH") in obese men. Each of the Company's product candidates has generated positive clinical data for Mereo's target indication or in a related indication. The Company's strategy is to selectively acquire product candidates that have already received significant investment from pharmaceutical companies and that have substantial preclinical, clinical and manufacturing data packages. Since inception the Company has commenced large, randomized, placebo-controlled Phase 2 clinical trials for three of the product candidates and has previously announced positive top-line results from two of its clinical trials: a Phase 2 trial with BCT-197 in December 2017 and a Phase 2b dose-ranging study with BGS-649 in March 2018.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

ALSLLFSAARIFIIT